 AUSTIN, Texas , Jan. 5, 2022 PRNewswire -- Aeglea BioTherapeutics, Inc. Nasdaq:AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows: Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022 Live Presentation DateTime: Wednesday, January 12 at 10:30 a.m. 